Imaging and clinical factors impacting PSA response in patients with metastatic castrate resistant prostate cancer undergoing Lu177-PSMA-617 therapy.

Sarah Boughdad; MARIE MEYER; Michael Da Mota; Gilles Allenbach; Marie Nicod-Lalonde; John Prior; Niklaus Schaefer

Meeting ReportOral - PhysicianPharm

Imaging and clinical factors impacting PSA response in patients with metastatic castrate resistant prostate cancer undergoing Lu177-PSMA-617 therapy.

Sarah Boughdad, MARIE MEYER, Michael Da Mota, Gilles Allenbach, Marie Nicod-Lalonde, John Prior and Niklaus Schaefer

Journal of Nuclear Medicine May 2021, 62 (supplement 1) 80;

Sarah Boughdad

1CHUV Lausanne Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

MARIE MEYER

1CHUV Lausanne Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michael Da Mota

1CHUV Lausanne Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Gilles Allenbach

2Chuv Epalinges Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Marie Nicod-Lalonde

1CHUV Lausanne Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

John Prior

3Lausanne University Hospital La Conversion Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Niklaus Schaefer

1CHUV Lausanne Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics

Article Figures & Data

Figures

Download figure
Open in new tab
Download powerpoint
Download figure
Open in new tab
Download powerpoint

In this issue

Journal of Nuclear Medicine

Vol. 62, Issue supplement 1

May 1, 2021

Table of Contents
Index by author

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Imaging and clinical factors impacting PSA response in patients with metastatic castrate resistant prostate cancer undergoing Lu177-PSMA-617 therapy.

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Imaging and clinical factors impacting PSA response in patients with metastatic castrate resistant prostate cancer undergoing Lu177-PSMA-617 therapy.

Sarah Boughdad, MARIE MEYER, Michael Da Mota, Gilles Allenbach, Marie Nicod-Lalonde, John Prior, Niklaus Schaefer

Journal of Nuclear Medicine May 2021, 62 (supplement 1) 80;

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Imaging and clinical factors impacting PSA response in patients with metastatic castrate resistant prostate cancer undergoing Lu177-PSMA-617 therapy.

Sarah Boughdad, MARIE MEYER, Michael Da Mota, Gilles Allenbach, Marie Nicod-Lalonde, John Prior, Niklaus Schaefer

Journal of Nuclear Medicine May 2021, 62 (supplement 1) 80;

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Info & Metrics

No related articles found.

Google Scholar

Cited By...

No citing articles found.

Google Scholar

Oral - PhysicianPharm

Preclinical Evaluation of a novel PET Tracer for imaging PARP1 in Glioblastoma
Aspirin blockade of COX-1 in human organs is reduced by plasma as shown by PET imaging and blood assays with ¹¹C-PS13
Study evaluating the prognostic value of PET parameters after 177Lu-DOTATATE Peptide Receptor Therapy in NET patients

Show more Oral - PhysicianPharm

Cancer Radiopharmaceutical Therapy

Relationship of Marrow Radiation Dose and Timing of Engraftment for Targeted Radioimmunotherapy with Anti-CD45 Iodine (¹³¹I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
²²⁵Ac-PSMA-617 Targeted Alpha Therapy in Metastatic Castration Resistant Prostate Cancer Patients
Blood based genomic assessment of the clinical efficacy and toxicity of peptide receptor radionuclide therapy (PRRT)

Show more Cancer Radiopharmaceutical Therapy

Main menu

User menu

Search

Imaging and clinical factors impacting PSA response in patients with metastatic castrate resistant prostate cancer undergoing Lu177-PSMA-617 therapy.

Article Figures & Data

Figures

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Oral - PhysicianPharm

Cancer Radiopharmaceutical Therapy

Similar Articles